DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $7,755,442 | +5.6% | 33,524 | +13.2% | 0.94% | -18.8% |
| Q3 2023 | $7,346,986 | +10.0% | 29,613 | +6.5% | 1.16% | +10.7% |
| Q2 2023 | $6,676,080 | -7.6% | 27,817 | -3.0% | 1.04% | -11.1% |
| Q1 2023 | $7,224,475 | +92855.2% | 28,664 | -2.1% | 1.18% | -4.2% |
| Q4 2022 | $7,772 | -99.9% | 29,284 | -0.7% | 1.23% | -4.5% |
| Q3 2022 | $7,620,000 | +0.7% | 29,500 | -1.2% | 1.29% | +5.8% |
| Q2 2022 | $7,568,000 | -14.8% | 29,852 | -1.5% | 1.22% | -3.0% |
| Q1 2022 | $8,885,000 | -15.7% | 30,292 | -5.4% | 1.25% | -33.0% |
| Q4 2021 | $10,538,000 | +6.7% | 32,029 | -1.3% | 1.87% | +3.5% |
| Q3 2021 | $9,877,000 | +32.1% | 32,443 | -2.4% | 1.81% | +42.7% |
| Q1 2021 | $7,478,000 | +2.5% | 33,228 | +1.2% | 1.27% | -3.5% |
| Q4 2020 | $7,294,000 | +33.8% | 32,833 | +29.7% | 1.31% | +25.2% |
| Q3 2020 | $5,452,000 | +21.8% | 25,320 | -0.0% | 1.05% | +11.4% |
| Q2 2020 | $4,478,000 | +29.5% | 25,327 | +1.4% | 0.94% | +17.9% |
| Q1 2020 | $3,457,000 | -11.6% | 24,973 | -2.0% | 0.80% | +11.3% |
| Q4 2019 | $3,911,000 | +9.3% | 25,483 | +2.9% | 0.72% | -1.4% |
| Q3 2019 | $3,577,000 | +1.2% | 24,768 | +0.1% | 0.73% | +2.3% |
| Q2 2019 | $3,536,000 | +11.9% | 24,739 | +3.3% | 0.71% | +18.5% |
| Q1 2019 | $3,161,000 | +30.7% | 23,942 | +2.0% | 0.60% | +12.4% |
| Q4 2018 | $2,419,000 | -1.2% | 23,462 | +4.1% | 0.53% | +6.4% |
| Q3 2018 | $2,448,000 | +12.9% | 22,534 | +2.5% | 0.50% | +7.5% |
| Q2 2018 | $2,168,000 | +74.0% | 21,974 | +72.7% | 0.47% | +67.4% |
| Q1 2018 | $1,246,000 | +27.0% | 12,725 | +20.4% | 0.28% | +24.0% |
| Q4 2017 | $981,000 | +8.2% | 10,570 | 0.0% | 0.22% | +4.7% |
| Q3 2017 | $907,000 | +1.7% | 10,570 | 0.0% | 0.22% | -4.0% |
| Q2 2017 | $892,000 | -54.6% | 10,570 | -51.4% | 0.22% | -18.8% |
| Q1 2017 | $1,963,000 | +135.7% | 21,737 | +103.1% | 0.28% | +26.6% |
| Q4 2016 | $833,000 | -1.2% | 10,700 | -0.5% | 0.22% | -9.9% |
| Q3 2016 | $843,000 | -23.7% | 10,750 | -1.7% | 0.24% | -26.0% |
| Q2 2016 | $1,105,000 | +5.0% | 10,937 | -1.4% | 0.33% | -1.5% |
| Q1 2016 | $1,052,000 | +3.1% | 11,087 | +0.9% | 0.33% | +2.2% |
| Q4 2015 | $1,020,000 | +8.7% | 10,987 | -0.2% | 0.32% | +7.3% |
| Q3 2015 | $938,000 | -5.2% | 11,005 | -4.7% | 0.30% | +12.6% |
| Q2 2015 | $989,000 | -0.1% | 11,550 | -0.9% | 0.27% | +8.5% |
| Q1 2015 | $990,000 | -99.9% | 11,657 | -62.5% | 0.25% | -33.3% |
| Q4 2014 | $1,232,766,000 | +139353.2% | 31,085 | +167.1% | 0.37% | +60.3% |
| Q3 2014 | $884,000 | -7.4% | 11,637 | -4.1% | 0.23% | -1.7% |
| Q2 2014 | $955,000 | -7.3% | 12,136 | -11.6% | 0.24% | -9.6% |
| Q1 2014 | $1,030,000 | -15.9% | 13,736 | -13.4% | 0.26% | -17.7% |
| Q4 2013 | $1,225,000 | -6.7% | 15,864 | -16.3% | 0.32% | -13.6% |
| Q3 2013 | $1,313,000 | +6.7% | 18,947 | -2.6% | 0.37% | -1.3% |
| Q2 2013 | $1,230,000 | – | 19,448 | – | 0.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |